Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 17/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | CASP1 | P29466 | 2/20 | 0.64 |
| ▸ | CASP7 | P55210 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20032548 | 0.89 | ALDH1A1 (0.64) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL23456872 | 0.89 | ALDH1A1 (0.57) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL31412924 | 0.89 | ALDH1A1 (0.57) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL2063172 | 0.89 | ALDH1A1 (0.57) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL31412931 | 0.89 | ALDH1A1 (0.57) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL6431438 | 0.88 | ALDH1A1 (0.62) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL6354110 | 0.88 | ALDH1A1 (0.62) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL2176399 | 0.88 | ALDH1A1 (0.62) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL15010761 | 0.88 | ALDH1A1 (0.62) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL6250003 | 0.88 | ALDH1A1 (0.62) | ALDH1A1HSD17B10MAPK1CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957233-B1 | Process for preparing substituted quinolin-4-ol compounds | CALITOR SCIENCES, LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957233-B1 | Process for preparing substituted quinolin-4-ol compounds | CALITOR SCIENCES, LLC (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2018026877-A1 | PROCESS FOR PREPARING SUBSTITUTED QUINOLIN-4-OL COMPOUNDS | CALITOR SCIENCES, LLC (US) | 2018-02-08 | — | — | WO | disclosed |
| EP-2408300-B1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-05-11 | — | — | EP | disclosed |
| WO-2013180949-A1 | SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE | XI NING (US) | 2013-12-05 | — | — | WO | disclosed |
| US-8232294-B2 | Amino ester derivatives, sailts thereof and methods of use | Xi, Ning (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2408300-A1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd (CN) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010111063-A1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | XI NING (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100239576-A1 | AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239576-A1 | AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE | SRC, BCAT1, BCAT2 | ALDH1A1 2796/4885HSD17B10 2848/4885MAPK1 311/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | ALDH1A1 3139/4885HSD17B10 3782/4885MAPK1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.